Skip to main content
Verified Statutory Healthcare Resource — Indian Pharmacopoeia (IP) / CDSCO / PMBJP Jan Aushadhi Standards
Vitamins & Supplements 5 min read • Last Updated: September 2026

Liv.52 (Himalaya): Fatty Liver, Appetite Improvement & Ayurvedic Herb Safety

Comprehensive review of Himalaya Liv.52: Himsra, Kasani, Capparis spinosa herbal hepatoprotection, appetite stimulation, and non-alcoholic fatty liver...

Statutory Medical Disclaimer & Emergency Safety Notice The pharmacological and therapeutic data presented in this educational guide is synthesized exclusively for public health literacy, academic reference, and educational purposes in conformity with the Indian Pharmacopoeia (IP 2022) and guidelines established by the Central Drugs Standard Control Organisation (CDSCO). This content does not constitute medical diagnosis, formal physician opinion, or individualized therapeutic instruction. Under the Drugs and Cosmetics Act, 1940 and the National Medical Commission (Professional Conduct) Regulations, Schedule H, H1, and X pharmaceutical formulations must be prescribed and monitored by a registered medical practitioner (RMP). Patients must not initiate, alter, or terminate any therapeutic drug regimen without formal clinical evaluation by their treating physician or a licensed healthcare professional. For acute medical emergencies, dial 112 / 108 (India) immediately.
🩺 Quick Clinical Answer

Himalaya Liv.52 is an Ayurvedic herbal formulation containing Capparis spinosa (Himsra), Cichorium intybus (Kasani), Mandur bhasma, and other botanical extracts. It is widely used in India as a supportive hepatoprotective agent to restore hepatic parenchymal architecture, reduce elevated liver enzymes, and stimulate appetite in chronic hepatitis and early fatty liver.

1. Hepatoprotective Botanical Mechanisms

Herbal extracts in Liv.52 preserve the functional integrity of cell membranes in hepatocytes, prevent intracellular glutathione depletion, and accelerate cytochrome P450 enzyme recovery in injured liver tissue.

2. Supportive Care in Non-Alcoholic Fatty Liver Disease (NAFLD)

Liv.52 is used as a supportive supplement alongside dietary modifications and exercise for Grade 1 and Grade 2 hepatic steatosis (fatty liver). However, it is not a standalone cure for advanced liver cirrhosis or acute viral hepatitis.

3. Dosage and Safety Profile

Standard adult dosage is 2 tablets twice daily after meals, or 2 teaspoons of syrup twice daily. Decades of clinical usage show high safety and tolerability with no documented hepatotoxicity.

PMBJP Jan Aushadhi Price Transparency

Top 8 Essential Indian Medicines: Branded MRP vs. Jan Aushadhi Generic Comparison

Compare average Indian retail MRP of top branded formulations against government-certified PMBJP Jan Aushadhi bioequivalent generic prices and active salts. Verified against official PMBJP formularies, NPPA price caps, and CDSCO regulatory registries.

Brand Name Leading Manufacturer Active Salt Formulation (IP) Branded MRP Jan Aushadhi Price Savings %
Augmentin 625 Duo GlaxoSmithKline Pharmaceuticals Amoxicillin Trihydrate 500mg + Potassium Clavulanate 125mg IP ₹220.00 ₹58.00 74%
Dolo 650 Micro Labs Ltd Paracetamol (Acetaminophen) 650mg IP ₹34.00 ₹5.50 84%
Pantocid 40 Sun Pharmaceutical Industries Pantoprazole Sodium 40mg IP (Gastro-resistant) ₹155.00 ₹8.00 95%
Azithral 500 Alembic Pharmaceuticals Azithromycin Dihydrate 500mg IP ₹132.00 ₹24.00 82%
Glycomet 500 USV Private Limited Metformin Hydrochloride 500mg IP ₹24.00 ₹4.50 81%
Shelcal 500 Torrent Pharmaceuticals Elemental Calcium 500mg + Cholecalciferol (Vit D3) 250 IU IP ₹134.00 ₹16.00 88%
Telma 40 Glenmark Pharmaceuticals Telmisartan 40mg IP ₹92.00 ₹7.50 92%
Montair-LC Cipla Ltd Montelukast Sodium 10mg + Levocetirizine Dihydrochloride 5mg IP ₹210.00 ₹18.00 91%
Combined 8-Drug Essential Therapy Basket Total: ₹1,001.00 ₹141.00 85.9% Net Savings
Additional high-volume Indian medicines bioequivalent generic savings: Atorva 10 (Atorvastatin 10mg: Branded ₹110.00 vs Jan Aushadhi ₹12.00, 89% savings), Allegra 120 (Fexofenadine 120mg: Branded ₹215.00 vs Jan Aushadhi ₹32.00, 85% savings). Official Portal: PMBJP National Formulary (janaushadhi.gov.in) →

Frequently Asked Questions (Clinical & Regulatory)

Q1: Does Liv.52 cure alcohol damage if a person continues drinking?

NO. Liv.52 cannot protect against ongoing heavy alcohol consumption. The only effective treatment for alcoholic liver disease is complete abstinence from alcohol.

Q2: What is the difference between Liv.52 and Liv.52 DS?

Liv.52 DS (Double Strength) contains twice the concentration of active herbal ingredients per tablet, allowing a lower pill burden (1 tablet DS vs 2 regular tablets).

Q3: Why should Calcium and Iron supplements never be co-ingested at the same meal?

Calcium competitively binds and blocks divalent metal transporter 1 (DMT1) on the luminal surface of enterocytes, reducing non-heme iron absorption by up to 60%. Patients should space calcium and iron tablets by at least 3 to 4 hours.

Q4: What is the standard clinical dosing protocol for Vitamin D3 (Cholecalciferol 60,000 IU)?

In documented hypovitaminosis D (<20 ng/mL), clinical protocols recommend 60,000 IU cholecalciferol once weekly for 8 consecutive weeks, followed by once-monthly maintenance, ingested with a dietary fat source for micellar absorption.

Q5: Are PMBJP Jan Aushadhi multivitamin and mineral supplements bioequivalent to brands like Shelcal 500?

Yes. Jan Aushadhi Calcium 500mg + Vitamin D3 and B-complex formulations comply with Indian Pharmacopoeia nutritional monographs and provide identical elemental mineral potency at an average 80% savings.

MediMatch AI Clinical Pharmacology Review Board
Clinically reviewed by Dr. Vikram Anand, MBBS, MD (Clinical Pharmacology), Dr. Aditi Sharma, MD Pharmacology & Dr. Rajesh Nair, PharmD, RPh

This clinical guide is authored and reviewed in accordance with the regulatory standards of the Indian Pharmacopoeia (IP), Central Drugs Standard Control Organization (CDSCO) drug schedules, and Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) bioequivalence guidelines. All therapeutic recommendations and drug interaction warnings are cross-referenced with official statutory publications.

Official Statutory References: Indian Pharmacopoeia Commission (ipc.gov.in) → PMBJP Jan Aushadhi Portal (janaushadhi.gov.in) → CDSCO Health & Family Welfare (cdsco.gov.in) →
Digital Personal Data Protection (DPDP) Act, 2023 Statutory Health Privacy Disclosure

Under India's Digital Personal Data Protection (DPDP) Act, 2023, MediMatch AI functions as a data fiduciary committed to zero retention of private health identifiers. Browsing educational guides, reviewing active salt monographs, and executing search queries occur without tracking or commercial profiling. All client interactions with prescription readers or lab decoders execute ephemerally in volatile memory with zero server-side storage of protected health information (PHI). For inquiries regarding data fiduciary obligations, contact our Data Protection Officer at privacy@medimatchai.in.